{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T07:48:16Z","timestamp":1788680896309,"version":"build-2803163510"},"reference-count":0,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n\t  <jats:sec id=\"S031716712400338X_as1\">\n\t    <jats:title>Background:<\/jats:title>\n\t    <jats:p>Disease-modifying therapies (DMTs) for Alzheimer\u2019s disease (AD) are emerging following successful clinical trials of therapies targeting amyloid beta (A\u03b2) protofibrils or plaques. Determining patient eligibility and monitoring treatment efficacy and adverse events, such as A\u03b2-related imaging abnormalities, necessitates imaging with MRI and PET. The Canadian Consortium on Neurodegeneration in Aging (CCNA) Imaging Workgroup aimed to synthesize evidence and provide recommendations on implementing imaging protocols for AD DMTs in Canada.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S031716712400338X_as2\">\n\t    <jats:title>Methods:<\/jats:title>\n\t    <jats:p>The workgroup employed a Delphi process to develop these recommendations. Experts from radiology, neurology, biomedical engineering, nuclear medicine, MRI and medical physics were recruited. Surveys and meetings were conducted to achieve consensus on key issues, including protocol standardization, scanner strength, monitoring protocols based on risk profiles and optimal protocol lengths. Draft recommendations were refined through multiple iterations and expert discussions.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S031716712400338X_as3\">\n\t    <jats:title>Results:<\/jats:title>\n\t    <jats:p>The recommendations emphasize standardized acquisition imaging protocols across manufacturers and scanner strengths to ensure consistency and reliability of clinical treatment decisions, tailored monitoring protocols based on DMTs\u2019 safety and efficacy profiles, consistent monitoring regardless of perceived treatment efficacy and MRI screening on 1.5T or 3T scanners with adapted protocols. An optimal protocol length of 20\u201330 minutes was deemed feasible; specific sequences are suggested.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S031716712400338X_as4\">\n\t    <jats:title>Conclusion:<\/jats:title>\n\t    <jats:p>The guidelines aim to enhance imaging data quality and consistency, facilitating better clinical decision-making and improving patient outcomes. Further research is needed to refine these protocols and address evolving challenges with new DMTs. It is recognized that administrative, financial and logistical capacity to deliver additional MRI and positron emission tomography scans require careful planning.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1017\/cjn.2024.338","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T13:11:43Z","timestamp":1730725903000},"page":"1-9","source":"Crossref","is-referenced-by-count":3,"title":["Recommendations on Imaging in the Context of Alzheimer\u2019s Disease-Modifying Therapies from the CCNA Imaging Workgroup"],"prefix":"10.1017","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6326-0745","authenticated-orcid":false,"given":"Simon","family":"Duchesne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Louis","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bartha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Chertkow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Dadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Rosa-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Soucy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3956-1668","authenticated-orcid":false,"given":"Eric E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2024,11,4]]},"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S031716712400338X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T04:44:39Z","timestamp":1737348279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S031716712400338X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":0,"alternative-id":["S031716712400338X"],"URL":"https:\/\/doi.org\/10.1017\/cjn.2024.338","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]}}}